These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19765437)

  • 21. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
    Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial.
    Kim MJ; Tsinalis D; Franz S; Binet I; Gürke L; Mihatsch MJ; Steiger J; Thiel G; Dickenmann M
    Ann Transplant; 2008; 13(4):21-7. PubMed ID: 19034219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
    Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
    Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
    Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
    Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
    Ingle GR; Moudgil A; Vo A; Jordan SC
    Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
    Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
    Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
    Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis.
    Sellers MT; McGuire BM; Haustein SV; Bynon JS; Hunt SL; Eckhoff DE
    Transplantation; 2004 Oct; 78(8):1212-7. PubMed ID: 15502722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Sánchez-Fructuoso AI; Marques M; Conesa J; Ridao N; Rodríguez A; Blanco J; Barrientos A
    Transpl Int; 2005 May; 18(5):596-603. PubMed ID: 15819810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.
    Barsoum RS; Morsey AA; Iskander IR; Morgan MM; Fayad TM; Atalla NT; Wafik H; Grace RA; Adel N; Khalil SS
    Exp Clin Transplant; 2007 Dec; 5(2):649-57. PubMed ID: 18194116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
    Sheashaa HA; Bakr MA; Fouda MA; El-Dahshan KF; Ismail AM; Sobh MA; Ghoneim MA
    Int Urol Nephrol; 2007; 39(1):317-9. PubMed ID: 17333530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience.
    Post M; Raszeja-Wyszomirska J; Jarosz K; Lubikowski J; Wasilewicz M; Mydłowska M; Milkiewicz P; Wójcicki M
    Transplant Proc; 2009 Oct; 41(8):3107-9. PubMed ID: 19857687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.